Showing 742 results
-
Featured News /
-
Press release /European Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare…
-
Press release /Proposed acquisition builds on existing agreement with CellforCure for contract manufacturing of Novartis leading CAR-T cell therapy Kymriah® (tisagenlecleucel) and recent successful completion of…
-
In The News /Harald Nusser, Head of Novartis Social Business shares his insights following the latest National Malaria Control Program best practice sharing workshop in Dakar.
-
Pulse Update /
-
Ad hoc release /
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Ad hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD)Key growth drivers continued strong sales momentum including Entresto… -
Clinical Trials /
-
Clinical Trials /
-
Clinical Trials /
-
Press release /Cosentyx is the first and only IL-17A inhibitor from a new class of medicines shown to treat two of the most common inflammatory joint conditions in Europe[1] Cosentyx shows rapid and…